New weekly combo offers hope for head and neck cancer patients who can't take standard chemo
NCT ID NCT04858269
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 33 times
Summary
This study is for people with advanced head and neck cancer that has spread and cannot be treated with surgery or radiation. It tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus an immunotherapy drug (pembrolizumab) in patients who cannot take the standard chemo 5-fluorouracil. The goal is to see if this regimen shrinks tumors better than immunotherapy alone. About 32 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Health Sciences
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.